Stronger post-surgery treatment for triple-negative breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a stronger post-surgery treatment to reduce the chance of breast cancer coming back in women with a certain type of triple-negative breast cancer (one that also has high androgen receptor activity). If you already had chemo before surgery but it didn't completely eliminate the cancer, this might be an option for you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman between 18 and 70 years old.
- You have triple-negative breast cancer (tumors that are estrogen-negative, progesterone-negative, and HER2-negative) that also has high levels of androgen receptor (AR).
- You had surgery for early-stage breast cancer (cancer that hasn't spread to distant organs).
- You received at least 4 rounds of chemotherapy before surgery, but the cancer was not completely gone after that chemo.
- You do not have a BRCA1 or BRCA2 gene mutation.
- You are generally healthy enough for treatment, with adequate organ function (like blood counts and kidney/liver function).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether adding a drug called everolimus to a targeted therapy called trastuzumab rezetecan is more effective than the targeted therapy alone for people with a specific type of triple-negative breast cancer (called LAR subtype) that has spread or come back. The combination aims to improve treatment response and potentially help you live longer.
This trial tests a combination of an immunotherapy drug (QL1706) plus standard chemotherapy given before surgery to shrink triple-negative breast cancer. The goal is to see if this approach helps remove the tumor more completely.
This trial tests whether people with early stage triple-negative breast cancer and a high level of immune cells in the tumor can safely skip chemotherapy after surgery. It aims to find a less intensive treatment option for those who may not need strong drugs.
This study tests giving a combination of chemotherapy and immunotherapy before surgery for early stage triple negative breast cancer. The goal is to see if this approach can improve treatment outcomes and reduce the chance of the cancer coming back.
This trial tests whether adding more treatment after surgery can help people with triple-negative breast cancer who still have cancer cells left after initial chemotherapy and immunotherapy. It aims to reduce the chance of cancer coming back.
This trial tests whether adding an immunotherapy drug (camrelizumab) to standard chemotherapy before surgery can improve outcomes for women with early-stage triple-negative breast cancer. The treatment is given before surgery to shrink tumors and may help prevent the cancer from coming back.
Hear when a new Breast Cancer Females trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.